natgillin/translations-raw huggingface dataset:
means (704-0) for mapping the FECFrame onto a Quadrature Amplitude Modulation, QAM, constellation to build a complex forward error correction Frame, XFEC Frame; means (705-0) for inserting an FECFrame Header in front of the XFEC Frame; 
Low Density Parity Check, LDPC), koja kodiraju vanjski kodirane PLP podatke za unaprijedno ispravljanje pogrešaka i izlaz, okvir za unaprijedno ispravljanje pogrešaka (eng. forward error correction Frame, FECFrame) za LDPC kodirane PLP podatke; sredstva (704-0) za mapiranje FEC okvira na konstelaciji kvadraturne amplitudne modulacije (eng.
is hydrogen; and is C1-4 aliphatic The composition of any one of clauses 34-36, wherein R4 and R5, taken together with the intervening oxygen and boron atoms, form an optionally substituted 5-membered ring. 
(b) R' je vodik: i (o) R! je C, alifatik; ili (c) gdje R' i R', uzeti zajedno sa atomima kisika i bora koji se nalaze između, formiraju izborno supstituirani 5-člani prsten; ili
An optoelectronic device as claimed in claim 8, wherein a first side and a second side of the channel (302) provide the positive and negative poles of an electrical circuit, the first and second sides being in electrical communication with the conductor material (318) on the first and second faces of the channel (302). 
Optoelektronički uređaj prema patentnom zahtjevu 8, naznačen time što prva strana i druga strana kanala (302) osiguravaju pozitivne i negativne polove električnog kruga, gdje su prve i druge strane s u električnoj komunikaciji s vodičkim materijalom (318) na prvim i drugim prednjim stranama kanala (302).
acryl amide or acrylic esters such as methylmethacrylate, or mixtures thereof; alkali polyphosphates; or mixtures thereof, and wherein 
akril amid ili akrilni esteri kao što je metilmetakrilat, ili njihove mješavine; alkalni polifosfati; ili njihove mješavine, te pri čemu
is hydrogen, fluorine, chlorine or a methoxy group; 
je vodik, fluor, klor ili metoksi skupina;
align said loading form with respect to said loading members, with said first central axis basically coincident with said second central axis; introduce the loading form into an inner space of the loading members, placing the portion of knitted article wrapped outside the loading form in front of the fabric strip wrapped around the loading members, so that the fabric strip surrounds outside the end portion of the knitted article and lies concentrically with respect to the latter; 
- umetanja kalupa za punjenje (11) u unutarnji prostor (32) naprava za punjenje (31), stavljanja dijela pletenog artikla na takav način da se omota izvan kalupa za punjenje ispred trake od tkanine omotane oko naprava za punjenje, na takav način da traka od tkanine okružuje s vanjske strane krajnjeg dijela pletenog artikla i leži koncentrično u odnosu na potonji;
The combination, combination for use or immune checkpoint inhibitor for use of claims 1-9, wherein the anti-immune checkpoint protein antibody is an anti-PD-1 antibody, derivative thereof, or antigen-binding fragment thereof, selected from among: 
Kombinacija, kombinacija za uporabu ili inhibitor imunološke kontrolne točke za uporabu prema zahtjevima 1-9, pri čemu je proteinsko antitijelo anti-imunološke kontrolne točke anti-PD-1 antitijelo, njegov derivat ili njegov antigen-vezujući fragment, odabran od između: a)
The method of Claim 5 further comprising a preparation of the compound of formula (12), or a pharmaceutically acceptable salt thereof, wherein the method comprises treating a compound of formula (11): with an oxidizing agent under suitable conditions to form the compound of formula (12), or a pharmaceutically acceptable salt thereof. 
Postupak u skladu s patentnim zahjevom 7, naznačen time što se dodatno sastoji u razdvajanju spoja formule (I), ili njegove farmaceutski prihvatljive soli, u obliku smjese enantiomera, u uvjetima pogodnim za dobivanje spoja formule (I-S): [image], ili njegove farmaceutski prihvatljive soli, i spoja formule (I-R):
(FTC smoking conditions consist of two seconds of puffing (35 ml total volume) separated by 58 seconds of smolder). 
(FTC uvjeti za pušenje sastoje se od dvije sekunde uvlačenja dima (ukupne zapremnine 35 ml) odvojenih sa 58 sekundi).
Preferably m is 0 or 1 (more preferably 1). 
Najpoželjnije je m jednak 0 ili 1 (poželjnije 1).
at least one phosphate salt and optionally NaCl; the method comprising: aa) dissolving the compound of the formula (III) and/or (II): or with a buffer; 
(II) i b) najmanje jednu fosfatnu sol i izborno NaCI; naznačen time što se postupak sastoji u: aa) otapanju spoja formule (III) i/ili (ID):
According to the present invention, it is preferred that in case of a failure of the functionality of the home database, the result of the Provide Roaming Number (PRN) procedure is converted to a result of a Send Routing Info (SRI) procedure and delivered to the requesting entity. 
Metoda prema zahtjevu 2, naznačena time da se, u slučaju onesposobljenosti funkcije polazne baze podataka (14), rezultat postupka za dobivanje broja roaminga (PRN) konvertira u rezultat postupka slanja informacija o usmjeravanju poziva (SRI) i šalje tražitelju usluge (12).
an Sp35 antibody or antigen-binding fragment thereof; 
ii) Sp35 antitijelo ili njegov dio koji se veže za antigen;
In this invention the combination of polydextrose, inulin, oligofructose and resistant maltodextrin specifically results in an overall drop of the pH since it has been proven that oligofructose and oligosaccharide resistant maltodextrin are fermented in the upper part of the colon, while polysaccharide resistant maltodextrin, polydextrose and inulin are not fermented till the lower part of the colon. 
Kombinacijom polidekstroze, inulina, oligofruktoze 1 rezisterntnog maltodekstrina, prema ovom izumu, postiže se ukupno sniženje pH jer je dokazano da se oligofruktoza i maltodekstrin Tezistentan na oligosaharide fermentiraju u donjem dijelu debelog crijeva, dok se maltodekstrin rezistentan na polisaharide, polidekstroza 1 inulin fermentiraju sve do donjeg dijela debelog crijeva.
As shown above, in accordance with Determination Method 1, resource amount determining section 204 uses a CW with the lower coding rate of the coding rates of the plurality of CWs to determine the amount of the resource of control information in each layer. 
PUSCHdnIdal € produkt Mcwsisc a Lawa, i broja simbola prijenosa u svakom sloju kodne riječi Termimalni uređaj sukladno zahtjevu 1, naznačen time da je kontrolna informacija signal potvrdne/negativne potvrde, ACK/NACK.
The condition of memory impairment is manifested by impairment of the ability to learn new information and/or the inability to recall previously learned information. 
Stanje oslabljenog pamćenja očituje se kroz slabljenje sposobnosti za učenjem novih informacija i/ili nemogućnosti prisjećanja prethodno naučenih podataka.
comprises heavy and light chain variable regions having the amino acid sequences of SEQ ID NOs: 7 and 8 respectively, SEQ ID NOs: 17 and 18 respectively, SEQ ID NOs: 39 and 40 respectively or SEQ ID NOs: 49 and 18 respectively; 
sadržava varijabilne domene teških i lakih lanaca koje imaju aminokiselinske nizove SEQ ID NOs: 7 i 8, odnosno, SEQ ID NOs: 17 i 18, odnosno, SEQ ID NOs: 39 i 40, ili SEQ ID NOs: 49 i 18;
culturing the one or more mammalian cells in the copper supplemented cell culture media such that rA13 is expressed and excreted from the cells into a culture supernatant, wherein the culturing comprises continuous cultivation; and recovering at least a portion of the culture supernatant, 
uzgoja jedne ili više stanica u mediju za uzgoj stanica kompletiranom bakrom, tako da se rVWF eksprimira i izlučuje iz stanica u supernatant kulture, gdje se sadržaj NH4+ u supernatantu kulture stanica održava u koncentraciji ispod 4 mM; i
Thus the central server has so-to-speak ‘kicked’ the SIM off one network and onto another. According to a fourth aspect of the invention there is provided a communication device comprising: storage means for storing a list of subscriber network identifiers; processing means for determining, where a new network connection is required, which subscriber network identifier to use to make the new network connection according to selection rules stored in the storage means; and means to accept update information over a network connection, wherein the communication device operates on received update information to update the list of subscriber network identifiers and the selection rules. 
Komunikacioni uređaj koji obuhvaća: sredstvo (546) za skladištenje podataka radi smještanja liste pretplatnikovih mrežnih identifikacija; sredstvo (544) za procesiranje radi određivanja, kada je potrebna nova mrežna konekcija, koju pretplatničku mrežnu identifikaciju treba koristiti da bi se kreirala nova mrežna konekcija prema pravilima za izbor koja su smještena u sredstvu za skladištenje; i sredstvo za prihvaćanje informacija o ažuriranju preko mrežne konekcije, pri čemu informacije o ažuriranju obuhvaćaju pretplatničku mrežnu identifikaciju dobivenu postupkom prema bilo kom od zahtjeva 1 do 15 i pri čemu komunikacioni uređaj radi u skladu sa primljenim informacijama o ažuriranju da bi se ažurirala lista pretplatnikovih mrežnih identifikacija i pravila izbora.
The compound according to claim 1 or 2 which is characterized by an X-ray powder diffraction pattern obtained with CuKa radiaton with peaks at values of 2-theta (2θ) of 10.5 ° and 15.7 °. 
Spoj prema Zahtjevu 1 ili 2, naznačen time, da ima obrazac rendgenske difrakcije praha dobiven s CuKa radijacijom s vršnim vrijednostima od 2-theta (20) od 10,5 * i 15,7 .
A further aspect of the present invention relates to a nucleic acid molecule encoding a fusion protein as described herein. 
Molekula nukleinske kiseline koja kodira fuzijski polipeptid bilo kojeg zahtjeva 1-8, poželjno u operativnom spoju sa slijedom za kontrolu ekspresije.
In a further embodiment, the synthetic intron in the nucleic acid molecule is flanked by nucleic acid encoding the CH1 at its 5' end and nucleic acid encoding the Fc at its 3' end. 
Molekula nukleinske kiseline prema patentnim zahtjevima od 1 do 3, naznačena time, da nukleinska kiselina kodira protein oblaganja koji se nalazi unutar sintetičkog introna, pri čemu je nukleinska kiselina smještena između nukleinske kiseline koja kodira CHI i nukleinske kiseline koja kodira spojnicu-Fc ili Fc.
The compound of claim 1 where Y is optionally substituted C5-6 cycloalkyl, optionally substituted C5-6 cycloheteroalkyl, optionally substituted phenyl, or optionally substituted C5-6 heteroaryl. 
Spoj iz zahtjeva lili 2, naznačen time, da Y je po izboru supstituirani Cs.g cikloalkil, po izboru supstituirani Cs5.4 cikloheteroalkil, po izboru supstituirani fenil, po izboru supstituirani Cs.g heteroaril.,
Equilibrium binding of3H-nicotinic acid was performed in 96-well polypropylene plates. 
Ekvilibrijsko vezivanje *H-nikotinske kiseline je provedeno u 96-well (posudica) polipropilen pločama.
wherein BAA is a basic amino acid, 
CD) gdje BAA znači bazična aminokiselina.
The observed increase in dimethyldisulfide content of sample C was considerably higher than that of sample B. Dimethyldisulfide is a particularly foul smelling substance with an extremely high odour potency. 
Primijećeno povećanje sadržava dimetildisulfid u uzorku C je bilo značajno više nego u uzorku B. Dimetildisulfid je naročito smrdljiva tvar s izuzetno visokom potencijom mirisa.
The formulation of claim 1 wherein the flavoring agent further comprises artificial cherry flavor. 
Formulacija zahtjeva 2 gdje korigens ukusa sadrži umjetnu aromu višnje.
providing at least one candidate sequence which consists of an amino acid sequence modified by substituting one or two amino acid residues to an original amino acid sequence, wherein the original amino acid sequence is selected from the group consisting of SEQ ID NOs: 100, 80, and 101; 
osiguravanja najmanje jednog slijeda kandidata koji ima aminokiselinski slijed modificiran zamjenom jednog ili dva aminokiselinska ostatka u izvornom aminokiselinskom slijedu, gdje se izvorni aminokiselinski slijed se bira iz skupine koju čine SEQ ID NO:41, 44, 46, 48 i 78;
A platform (1) according to claim 3 or claim 4, wherein at least the bottom plane (2) comprises a layer (25) made of alveolar polymer. 
Platforma (1) u skladu sa patentnim zahtjevom 3 ili patentnim zahtjevom 4, gdje najmanje donja ravnina (2) sadrži sloj (25) koji je napravljen od alveolarnog polimera.
The patient is preferably a human, and may be a child (e.g. 
Pacijent je pogodno čovjek, i može biti dijete (na pr.
adding a particulate formation inhibitor ethylene diamine tetraacetic acid disodium salt, 
(b) dodavanje inhibitora formiranja čestica koji je etilendiamin-tetraoctena kiselina dinatrijeva sol,
The medical composition according to claim 1, wherein R1 represents a hydrogen atom, methyl group, ethyl group, propyl group, isopropyl group, tert-butyl group or hexyl group, 
Medicinska oftalmološka otopina za uporabu prema Zahtjevu 1, gdje R' predstavlja atom vodika, metil skupinu, etil skupinu, propil skupinu, izopropil skupinu, fert-butil skupinu ili heksil skupinu,
W is a bond or an oxygen atom; and 
W je veza ili atom kisika; i
This particular production method causes therapeutic hosiery items, particularly in the case of women's stockings, to be aesthetically very different from other kinds of hosiery item. 
Taj osobit način proizvodnje uzrokuje da su terapeutske čarape, posebno u slučaju ženskih visokih čarapa, estetski vrlo različite od drugih vrsta čarapa.
a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleotide reverse transcriptase inhibitor and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily. 
inhibitor nukleotidne reverzne transkriptaze; pri čemu su TMC278 i inhibitor nukleotidne reverzne transkriptaze i inhibitor nukleozidne reverzne transkriptaze terapeutski učinkoviti inhibitori HIV-a u dozi koja se može davati jednom dnevno.
a first polynucleotide encodes a protein having an amino acid sequence comprising a steroidogenic acute regulatory related lipid transfer (START) domain or a derivative or mutant thereof and 
prvi polinukleotid kodira za protein s amino-kiselinskom sekvencom koja ima ceramidni prijenosni protein CERT ili njegov derivat ili njegov mutant, i
Disruption of the cavity bubbles create high temperature and pressure, this is stated in literature as the reason for the radicals being produced with ultrasound. 
Djelovanje na mjehur šupljine stvara velike temperature i tlak, što je u literaturi navedeno kao razlog za nastajanje radikala uz ultrazvuk.
This fourth embodiment corresponds essentially to the third embodiment shown in FIG. 4, except for the structure of the piercer 11, which is not provided with a resilient collar. 
Ta četvrta izvedba uglavnom odgovara trećoj izvedbi prikazanoj na slici 4, osim što se tiče strukture bušila 11, koje nema elastičnog prstena.
From this study it emerges that the metabolite ad-ministered as such produces, at the systemic level, much higher concentrations than those measured after its formation as a result of administration of ST1469, as demonstrated by the pharmaco-kinetic parameters reported in Table 1. 
Iz ovog istraživanja proizlazi da metabolit koji se kao takav primjenjuje proizvodi, na nivou sustava, mnogo više koncentracije od onih izmjerenih nakon njegova formiranja kao rezultata primjene ST1469, kao što je pokazano farmakokinetičkim čimbenicima prikazanim u Tablici 1.
assigning, by a scheduler, a frequency resource to the terminal apparatus based on the resource block group size that is set by the frequency assignment setting section; characterized in that 
dodjele, od strane planifikatora, resursa frekvencije terminalnom uređaju na temelju veličine skupine blokova resursa koju postavlja sekcija postavljanja dodjele frekvencije;
In some embodiments, the method further comprises combining the recovered antibody with a pharmaceutically acceptable carrier, excipient, or carrier to prepare a pharmaceutical formulation comprising the humanized antibody. 
Farmaceutska formulacija koja obuhvaća protutijelo iz bilo kojeg od patentnih zahtjeva 1-10 i farmaceutski prihvatljiv nosač.
When that acoustic signal stops, the system is ready to function. 
Kad se taj zvučni signal prekine, sustav je spreman za upotrebu.
The method according to claim 5, wherein the calculation of the normalized cross-correlation xc(n) on a sliding time window is performed through the following equation: 
Postupak u skladu s patentnim zahtjevom 6, naznačen time što se normaliziranu križnu korelaciju xc(n) u kliznom vremenskom okviru izračunava sljedećom jednadžbom:
providing at least one candidate sequence which consists of an amino acid sequence modified by substituting 1 or two amino acid residues to an original amino acid sequence, wherein the original amino acid sequence is selected from the group consisting of SEQ ID NO: 194, 174, 178, and 186; 
(1) osiguravanja najmanje jednog slijeda kandidata koji ima aminokiselinski slijed modificiran zamjenom jednog ili dva aminokiselinska ostatka u izvornom aminokiselinskom slijedu, gdje se izvorni aminokiselinski slijed se bira iz skupine koju čine SEQ ID NO:41, 44, 46, 48 1 78;
The extract was analysed using gas-chromatography to identify unreacted FAME and fatty acids. 
Ekstrakt je analiziran plinskom kromatografijom zbog dokazivanja neizreagiranog FAME-a i masnih kiselina.
A method according to claim 1, wherein said fibre cement material is added in an amount of at least 10 wt. %, based on the total weight of raw clinker meal and fibre cement material. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 11, naznačen time što se navedeni materijal od vlaknastog cementa dodaje u količini od najmanje 5 mas.% i poželjno od najmanje 10 mas.%, bazirano na ukupnoj masi sirovog klinkerskog kolača i materijala od vlaknastog cementa.
The pharmaceutical composition of claim 1 wherein the compound of formula IIB is the compound of formula IIBa or a pharmaceutically acceptable salt, solvate, and/or ester thereof. 
HR P20161428 T1 5. Farmaceutski sastav prema patentnom zahtjevu 1 pri čemu je spoj formule IIB spoj formule IIBa: koj
A MEMS microphone with a built-in textile material protecting screen, according to claim 1, characterized in that, when said MEMS microphone is mounted at a top mounting or assembling position, said textile screen is made of conventional materials such as PET, PA, PP or other polymers, if the environmental conditions do not involve a comparatively high temperature. 
MEMS mikrofonski uređaj (1), u skladu s patentnim zahtjevom 1, naznačen time što je, kada se navedeni MEMS mikrofon (1) montira na gornjem ugradbenom položaju na navedenoj tiskanoj pločici (PCB) (7), navedeni tekstilni zaslon je načinjen od bilo kojeg od PET, PA i PP.
Advantages of Aspects of the Invention. 
Broj objave europskog patenta:
A peptide according to any one of claims 1 to 4, the cell according to claim 7, or the activated cytotoxic T lymphocyte according to claim 11 for use in the treatment of cancer. 
Peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 4 za uporabu u liječenju karcinoma ili za uporabu u proizvodnji cjepiva protiv karcinoma.
The hinge preferably allows the sides to be rotated relative to each other within an angle of 180° or more, such as 190° or 200° or 210° or 220° or 230° or 240° or more than 240°. 
Poželjno je da pant omogućava zakretanje jedne strane u odnosu na drugu pod kutom od 180? ili više, pod takvim kutom kao što je 190% ili 200% ili 210% ili 220% ili 240% ili više od 240%.
an isolated antibody that competes with a monoclonal antibody 88M1 produced by a hybridoma cell having ATCC deposit number PTA-9342 in a competitive binding assay. 
(c) izolirano protutijelo koje se natječe u natjecateljskom ispitivanju vezanja, s monoklonalnim protutijelom 88M1 proizvedenim pomoću stanične linije hibridoma koji ima broj ATCC depozita pod oznakom PTA-9342.
In some embodiments, provided is a double-stranded nucleic acid molecule wherein the antisense strand (SEQ ID NO:127) includes 2′OMe modified ribonucleotides at positions 1, 3, 5, 9, 11, 15, 17 and 19; a 2′-5′-ribonucleotide at position 7; and a C3Pi-C3OH moiety covalently attached to the 3′-terminus; and the sense strand (SEQ ID NO:60) is selected from a sense strand which includes 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što protusmisleni lanac sadrži SEQ ID NO:127, a smisleni lanac sadrži SEQ ID NO:60; gdje protusmisleni lanac dodatno sadrži 2'-0- metilom modificirane ribonukleotide; 2'-5'-ribonukleotid na najmanje jednom od položaja 1, 5, 6, ili
Verification of the new usage of 5a-androstane-3B,5,6B-triol 
Datum podnošenja europske prijave patenta:
RA and RB are independently selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl; and RC and RD are independently selected from the group consisting of hydrogen and alkyl. 
R, i R; su neovisno odabrani iz skupine koja se sastoji od vodika, alkila i alkilkarbonila; 1 Rc i Ry su neovisno odabrani iz skupine koja se sastoji od vodika i alkila.
Thus, in according with an advantageous embodiment of the invention the frying fat composition contains 3-30 wt.%, more preferably 5-25 wt.% of a red palm oil component, said red palm oil component being selected from the group consisting of red palm, red palm oil fractions and combinations thereof. 
- 25-60%, težinski, strukturne masti, koju se bira iz skupine koju čine palmino ulje, frakcije palminog ulja, laurinska mast, frakcije laurinske masti, posve hidrogenirano biljno ulje, i njihove kombinacije; gdje ulje crvene palme sadrži najmanje 200 ppm karotenoida i 200 ppm tokotrienola.
The reagent of claim 33, characterized in that the a at least one kosmotrope is selected from the group consisting of Glycerol, Trimethylamine N-oxide, Ectoine, aa-Trehalose, 3-Dimethylsulfoniopropionate, Glucose, Dextran, or D-Lactose. 
Kemijski modificirana molekula FVIII, namijenjena upotrebi u skladu s patentnim zahtjevom 5, naznačena time što se poremećaj zgrušavanja krvi bira iz skupine koju čine hemofilija A i von Willebrandov sindrom.
The method of claim 13, wherein the low conductivity wash buffer has a conductivity less than the conductivity of a 150 mM sodium chloride solution, less than the conductivity of a 120 mM sodium chloride solution, less than the conductivity of a 90 mM sodium chloride solution, less than the conductivity of a 60 mM sodium chloride solution, less than the conductivity of a 40 mM sodium chloride solution, or less than the conductivity of a 20 mM sodium chloride solution. 
Postupak u skladu s patentnim zahtjevom 13, naznačen time što niskovodljivi pufer za ispiranje ima vodljivost nižu od vodljivosti 150 mM otopine natrijevog klorida, nižu od vodljivosti 120 mM otopine natrijevog klorida, nižu od vodljivosti 99 mM otopine natrijevog klorida, nižu od vodljivosti 60 mM otopine natrijevog klorida, nižu od vodljivosti 40 mM otopine natrijevog klorida, ili nižu od vodljivosti 20 mM otopine natrijevog klorida.
The process according to claim 1 or 2 wherein, alkoxy is methoxy. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da je alkoksi metoksi.
m is 0, 1 or 2; if m is 2 then R1 may be the same or different; 
m je 0, 1 ili 2; ako m je 2, tada R1 može biti isti ili drugačiji;
wherein two R13 or two R14 on the same N can cyclize to form a 4-6 membered heterocyclic ring optionally substituted with C1-4 alkyl, C1-4 alkoxy, hydroxy, amino or oxo; 
pri čemu dva R13 ili dva R14 na istom N mogu ciklirati kako bi tvorili 4-6-člani heterociklični prsten izborno supstituiran s C1-4 alkil, C1-4 alkoksi, hidroksi, amino ili okso;
Since only approx. 1% of CSGS 10A particles were used the top coating is transparent. 
Kako je korišteno samo oko 1 % CSGS 10A čestica, gornji sloj je proziran.
is a substituted or unsubstituted and 
ž i R? je supstituiran ili nesupstituiran fenil.